-+ 0.00%
-+ 0.00%
-+ 0.00%
Immuneering Plans Phase 2 Trial of Atebimetinib in Anaplastic Thyroid Cancer
Share
Listen to the news
Immuneering Plans Phase 2 Trial of Atebimetinib in Anaplastic Thyroid Cancer
  • Immuneering presented preclinical findings supporting a planned Phase 2 trial of atebimetinib with chemotherapy in second-line anaplastic thyroid cancer.
  • Results presented November 18, 2026, at the EORTC-NCI-AACR Symposium showed anti-tumor activity across genetically diverse cell models.
  • The combination controlled tumors better than chemotherapy alone or dabrafenib with trametinib in an animal model, including following targeted therapy.
  • Trial enrollment will include patients previously treated with targeted therapy for BRAF V600E-mutant disease, alongside patients without that mutation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180730PRIMZONEFULLFEED9880105) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending